医学
多发性骨髓瘤
硼替佐米
内科学
化疗所致周围神经病变
周围神经病变
肿瘤科
胃肠病学
作者
Annemiek Broyl,Joost L.M. Jongen,Pieter Sonneveld
标识
DOI:10.1053/j.seminhematol.2012.04.001
摘要
Introduction of the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals, The Takeda Oncology Company, Cambridge, MA) has substantially improved outcomes for patients with multiple myeloma (MM), and has become one of the cornerstones of current anti-myeloma treatment regimens. However, with the introduction of bortezomib it has become clear that peripheral neuropathy (PN) is one of the most frequent, potentially disabling, nonhematologic complications of bortezomib, often requiring dose modification or discontinuation, with a potential negative impact on clinical endpoints and quality of life. To find a balance between maximal benefit of bortezomib treatment, while maintaining quality of life, it is necessary to minimize toxicity. Here, we discuss all aspects of bortezomib-induced peripheral neuropathy (BiPN), and elaborate on the mechanisms underlying the development of BiPN.
科研通智能强力驱动
Strongly Powered by AbleSci AI